Skip to content

Determination of ED50 for a novel mixture of propofol, alfentanil, and lidocaine to inhibit body movement in cataract patients using Dixion's up-and-down sequential allocation method

Determination of ED50 for a novel mixture of propofol, alfentanil, and lidocaine to inhibit body movement in cataract patients using Dixion's up-and-down sequential allocation method

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042644
Enrollment
Unknown
Registered
2021-01-24
Start date
2021-02-01
Completion date
Unknown
Last updated
2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract surgery

Interventions

Group A1: age74 years old:Increase or decrease the concentration of 6-2-2 regimen depending on the OAA/S score (positive/negative)

Sponsors

Zhongshan Ophthalmic Center, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adult patient who is older than 18 years old; 2. Patient who receives monocular cataract surgery under basal anesthesia with intravenous drip; 3. ASA physical status with I to III; 4. Body mass index ranges from 18.5 to 23.9 kg/cm2; 5. Patient or his/her legal guardian voluntarily participants in the study and signs the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patient having severe cardiopulmonary dysfunction; 2. Patient having uncontrolled hypertension; 3. Electrocardiography examination discovers that patient with severe arrhythmia (eg. advanced A-V block, etc.) or apparent myocardial ischemia; 4. Patient having psychiatric disease or cognitive disorder which might affect the accuracy of somatosensory tests in this study; 5. Patient takes hypnotic, analgesic or antidepressant on a regular, continued basis, or in large quantities; 6. Patient having a history of alcohol abuse 7. Patient having a history of allergy or hypersensitivity to propofol, fentanyl or lidocaine 8. Any other factor that makes the investigator determines the patient is unsuitable for this study.

Design outcomes

Primary

MeasureTime frame
Modified Observer's Assessment of Alertness/sedation;

Secondary

MeasureTime frame
the occurrence of adverse events;

Countries

China

Contacts

Public ContactXiaoliang Gan

Zhongshan Ophthalmic Center, Sun Yat-Sen University

ganxl@mail.sysu.edu.cn+86 13688893908

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026